Project Details
Description
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
| Status | Active |
|---|---|
| Effective start/end date | 10/30/25 → 10/29/36 |
Funding
- CSL BEHRING GMBH
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.